Vlado Perkovic's Publications

Young TK, Li JW, Kang A et alii
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Journal articles
2021
Diabetologia
Sen T, Li J, Neuen BL et alii
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Journal articles
2021
Diabetologia
Heerspink HJL, Xie D, Bakris G et alii
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Journal articles
2021
J Am Soc Nephrol
Rahimi K, Bidel Z, Nazarzadeh M et alii
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Journal articles
2021
The Lancet
Wheeler DC, Weir MR, Gogate J et alii
Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial
Conference Papers
2021
in DIABETOLOGIA
Kang A, Arnold R, Gallagher M et alii
Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial
Journal articles
2021
Clinical Journal of the American Society of Nephrology
Mann JFE, Buse JB, Idorn T et alii
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Journal articles
2021
Diabetes
Kalantar-Zadeh K, Jafar TH, Nitsch D et alii
Chronic kidney disease
Journal articles
2021
The Lancet
Neuen BL, Oshima M, Perkovic V et alii
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Journal articles
2021
Eur Heart J
Heerspink HJL, Stack AG, Terkeltaub R et alii
Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.
Journal articles
2021
Nephrol Dial Transplant
Yeung E, Bello AK, Levin A et alii
Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey
Journal articles
2021
BMJ Open
Wang KM, Li JW, Bhalla V et alii
Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
Journal articles
2021
Endocrinology
Arnott C, Li JW, Cannon CP et alii
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Conference Abstracts
2021
in Diabetes
Jun M, Harris K, Heerspink HJL et alii
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
Journal articles
2021
Diabetes
Koomen JV, Stevens J, Bakris G et alii
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Journal articles
2021
Clinical Pharmacology and Therapeutics
Perkovic V, Blackorby A, Cizman B et alii
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS
Journal articles
2021
Nephrology Dialysis Transplantation
Perkovic V, Rovin B, Zhang H et alii
MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS
Journal articles
2021
Nephrology Dialysis Transplantation
Wheeler DC, Weir M, Gogate J et alii
FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL
Journal articles
2021
Nephrology Dialysis Transplantation
Weir MR, Slee A, Sun T et alii
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
Journal articles
2021
CLINICAL KIDNEY JOURNAL
Adler A, Agodoa L, Algra A et alii
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Journal articles
2021
The Lancet
Zhou Z, Jardine MJ, Li Q et alii
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
Journal articles
2021
Stroke
Yu J, Li J, Leaver PJ et alii
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.
Journal articles
2021
Cardiovasc Res
Nataatmadja M, Krishnasamy R, Zuo L et alii
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis
Journal articles
2021
Kidney International Reports
Copland E, Canoy D, Nazarzadeh M et alii
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
Journal articles
2021
The Lancet Oncology
Oshima M, Jardine MJ, Agarwal R et alii
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Journal articles
2021
Kidney International
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
Journal articles
2021
ESC Heart Failure

Vlado Perkovic's Publications

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial

Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Chronic kidney disease

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.

Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country